YAFO Capital (Shanghai) acted as VivaVision's advisor on this transaction.

雅法担任维眸生物财务顾问，与Everads就长效视网膜疾病治疗药物开发达成合作

Tel Aviv, Israel and Shanghai, China, January 6, 2023 – VivaVision, a pharmaceutical company developing innovative therapies for ocular diseases, and Everads Therapy, a biotech company developing optimized retinal therapies by leveraging its novel suprachoroidal delivery technology, announced today that they are partnering to develop safer, more effective, and more durable treatments for retinal diseases.      、

以色列特拉维夫和中国上海，2023年1月6日--维眸生物，一家专注于眼科创新药物的生物科技公司，和Everads Therapy，一家聚焦创新脉络膜上腔眼底递送技术的生物科技公司，宣布合作：开发更安全、更有效、和更持久的创新疗法治疗视网膜疾病。

The two companies will develop certain undisclosed molecules of VivaVision for suprachoroidal delivery using Everads’ technology and expertise. The molecules selected are potent small molecules that work against well-validated therapeutic targets in retinal disease management, and that are designed to enable extended durability in the suprachoroidal space.         

本次合作，双方将选择维眸设计的创新小分子药物，通过Everads独具一格的脉络膜输送装置和专业技术达到在脉络膜上腔缓释给药的目的。维眸将针对有很好科学验证的视网膜疾病靶点，设计具有适合脉络膜上腔注射理化性质的高活性小分子。

The suprachoroidal space is a promising route of administration for therapies targeting the back of the eye. Recent clinical results, as well as the FDA’s approval of the first drug and accompanying delivery technology for suprachoroidal delivery, have further demonstrated the potential benefits of delivery via this route of administration. While the suprachoroidal space has long been of interest due to its ability to directly target the retina and choroid, a major hurdle to its use has been the availability of safe, reliable and efficient delivery technologies. Everads’ novel approach for suprachoroidal delivery has demonstrated its ability to rapidly and safely deliver drugs to the back of the eye. 

脉络膜上腔注射是一种靶向眼底疾病的极具潜力的药物递送手段。近期的临床结果以及FDA批准的第一款脉络膜上腔给药的药物及其伴随技术，进一步证明了通过这种脉络膜上腔给药的优势和潜能。由于脉络膜上腔注射可以直接将药物递送到脉络膜和视网膜，因此该递送技术一直得到长期的关注和研究。但是，安全、可靠和高效的给药技术一直是阻碍脉络膜上腔给药的应用的短板。Everads的创新脉络膜上腔给药技术显示了其具有快速和安全的眼底递送优势和潜能。

“We are excited about the potential of delivering our treatments for posterior eye diseases through the suprachoroidal space using Everads’ technology, an approach that we believe will demonstrate strong efficacy and durability, potentially bringing life-changing improvements to populations throughout the world,” commented Wang Shen, PhD, CEO of VivaVision.   

维眸生物的首席执行官沈旺博士表示：“我们很高兴能够同Everads进行本次的合作，Everads脉络膜上腔给药技术和维眸的创新药的结合会为视网膜疾病患者带来更安全有效、更持久便利的治疗选择，期待这些疗法能在未来给世界各地的患者们带来人生的改善。”

On YAFO Capital's advisory services, Dr. Shen commented, "I am very impressed by YAFO’s global reach, especially ex-US hot biotech spots like Israel, Japan and Europe.  YAFO helped us to comb through companies old and new in the field of ophthalmology, and find an excellent fit for VivaVision.  YAFO team is absolutely an 'A' team, experience, connection, and most importantly easiness to communicate!"        

针对雅法资本的顾问服务，沈旺博士评价道：“我对雅法资本的全球业务覆盖印象深刻，尤其是在以色列、日本和欧洲等美国以外的热门生物技术地区。雅法帮我们梳理了眼科领域的新老公司，找到了一家非常适合维眸生物的技术公司。雅法团队绝对是一个“A”级的团队，经验丰富，人脉广，最重要的是易于沟通！”

Victor Ye, YAFO Managing Partner & Head of China Division, commented on the transaction: “We are thrilled to see this cross border collaboration happening! Congratulations to VivaVision and Everads! The combination of novel molecules and innovative drug delivery system will have big potential to dramatically help patients in need worldwide. We expect more collaboration deals will happen in near future. YAFO is equipped with resources and skills to facilitate more successful collaborations like this for our clients.”         

叶多先生，雅法资本合伙人兼中国业务部负责人，评价道：“我们非常高兴能够帮助客户维眸生物达成这个跨境合作！祝贺维眸和Everads！新型分子和创新药物输送系统的结合将有巨大的潜力，极大地帮助全球有需要的患者。我们预计在不久的将来会有更多的合作交易发生。雅法拥有的广泛的国际资源和丰富的跨境交易经验，我们很乐意去帮助更多的客户达成全球合作。”

Moshe Weinstein, Executive Chairman and acting CEO of Everads, added, “We believe that VivaVision’s drug candidates and formulations offer significant potential for the treatment of retinal disease via suprachoroidal administration with our technology. We look forward to working together to increase treatment safety, effectivity and durability.” 

Everads执行董事长兼代理首席执行官Moshe Weinstein评论道：“我们认识到维眸生物的创新药物设计和制剂研发实力的潜力，配以我们的先进的脉膜上腔给药技术可以带来治疗视网膜疾病的最佳疗法。我们期待着共同努力，一起来提高视网膜疾病治疗的安全性、有效性和持久性。”

Under the terms of collaboration agreement, the companies will jointly conduct pre-clinical research activities, in order to identify lead candidates for future clinical development and commercialization. Everads and VivaVision will share costs of the research plan, and have rights in a future joint venture which will hold the commercialization rights of the research results.        

两家公司将共同开展临床前研究，以确定未来的临床及商业化开发。Everads和维眸生物将共同制定研发计划，分摊研发成本，共享研发成果，并在将来成立合资公司开发这些成果。

YAFO Capital (Shanghai) acted as VivaVision's advisor on this transaction.      

雅法资本（上海）在本合作中担当维眸生物的财务顾问。

About VivaVision Biotech

VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. Besides VVN001 program, VivaVision is developing VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious anterior uveitis and post operative inflammation. VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases. VivaVision is led by experienced drug hunters in the fields of ophthalmology. The company is inspired to be a global leader of ophthalmic drug discovery. VivaVision is backed by leading life sciences investors including Sequoia, Lapam, Cenova, GTJA, etc.

维眸生物是一家专注于眼科创新药研发领域的临床阶段生物科技公司，拥有国际一流的眼科创新药研发团队和技术平台，依托自主研发已经建立起具有全球竞争力的产品管线。除VVN001项目外，维眸生物正在开发VVN539用于治疗青光眼或高眼压症，VVN461用于治疗非感染性前葡萄膜炎和术后炎症。维眸生物还致力于发现和开发用于治疗其他前、后眼疾病的新疗法。

To learn more about VivaVision, visit: www.vivavisionbio.com

About Everads Therapy

Everads Therapy is a biotech company focused on optimizing treatment of retinal diseases using its proprietary suprachoroidal delivery technology. With the aim of overcoming challenges in current treatment methodologies for retinal and macular diseases,Everads’ delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies via suprachoroidal delivery. Everads has a number of collaborations in the areas of gene therapy, cell therapy and other modalities. Everads was founded within RAD Biomed, a leading biotech incubator in Israel, and its underlying technologies were licensed from the Sheba Tel Hashomer Medical Center. The technology was further developed and optimized in conjunction with DALI Medical Devices, who specialize in injectable drug delivery solutions.

Everads是一家生物科技公司，专注于利用其独特的脉络膜上腔给药技术优化视网膜疾病的治疗。Everads的给药系统有望通过脉络膜上给药提高现有和潜在药物的疗效和安全性，克服目前视网膜和黄斑疾病治疗方法的挑战。Everads在基因治疗、细胞治疗和其他方式领域有多个合作。Everads成立于以色列领先的生物技术孵化器RAD Biomed内，其专有技术获得了Sheba Tel Hashomer医疗中心的许可，该技术是与DALI医疗器械公司(专攻注射给药解决方案)合作进一步开发和优化的。

请访问：www.everads-therapy.com获取更多信息。

For more information, please visit www.everads-therapy.com

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years.

雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法全球医疗专注于医药跨境交易，基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续三年排名第一。

For more information, please visit www.yafocapital.com

Contact us

Wendi Xiang

wxiang@yafocapital.com

+86-137-3368-5995

View Recent YAFO Report
2022 China Licensing Transaction by Numbers

扫码获取雅法近期行业报告 

雅法资本《2022年度中国医药授权交易年度报告》，深度剖析最新医药跨境交易趋势和动态（附全年交易汇总表）